专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010120524A3 METHODS OF MODULATING AN IMMUNE RESPONSE TO A VIRAL INFECTION 审中-公开
标题翻译：调节对病毒感染的免疫应答的方法
公开(公告)号：WO2010120524A3
公开(公告)日：2010-12-09
申请号：PCT/US2010029408
申请日：2010-03-31
申请人： ALTAIR THERAPEUTICS INC , ISIS PHARMACEUTICALS INC , GREGORY SUSAN , KARRAS JAMES G , CROSBY JEFFREY R , YU ZHENGRONG , GEARY RICHARD S
发明人： GREGORY SUSAN , KARRAS JAMES G , CROSBY JEFFREY R , YU ZHENGRONG , GEARY RICHARD S
IPC分类号： C12N15/113 , A61K48/00 , C07K14/715
CPC分类号： C07K14/7155 , C12N15/1138 , C12N2310/11 , C12N2310/315 , C12N2310/321 , C12N2310/3341 , C12N2310/341 , C12N2310/346 , C12N2310/3525
摘要： Disclosed herein are methods for treating respiratory disorders via administration of antisense compounds targeting IL-4Ra. Provided herein, for example, are compositions and methods of modulating immune responses to a viral infection in a subject. Also provided, for example, are compositions and methods for managing, treating, ameliorating, preventing and/or delaying the onset of pulmonary inflammation, airway hyperreactivity and/or loss of lung function, or a symptom thereof in a subject during the course of or resulting from a viral infection. Further provided, for example, are compositions and methods of inducing or augmenting hypo-responsiveness, non-responsiveness or tolerance to a virus in a subject. Also provided, for example, are compositions and methods of enhancing the efficacy of a viral vaccine in a subject. In certain embodiments, the compositions and methods provided herein utilize an antisense compound 12 to 35 nucleobases in length targeted to a nucleic acid molecule encoding human IL-4 receptor alpha IL-4Ra, wherein said antisense compound inhibits expression of human IL-4Ra protein and/or expression of functional IL-4 and IL- 13 receptors.
摘要翻译：本文公开了通过施用靶向IL-4Ra的反义化合物来治疗呼吸系统疾病的方法。例如，本文提供调节受试者中病毒感染的免疫应答的组合物和方法。还提供了例如用于在过程中管理，治疗，改善，预防和/或延迟受试者的肺部炎症发作，气道高反应性和/或肺功能丧失或其症状的组合物和方法，由病毒感染引起。进一步提供的是例如诱导或增加受试者中对病毒的低反应性，非反应性或耐受性的组合物和方法。还提供了例如增强受试者中病毒疫苗功效的组合物和方法。在某些实施方案中，本文提供的组合物和方法利用长度为靶向编码人IL-4受体α-IL-4Ra的核酸分子的反义化合物12至35个核碱基，其中所述反义化合物抑制人IL-4Ra蛋白的表达和 /或功能性IL-4和IL-13受体的表达。

2. 发明申请

WO2010120511A3 METHOD OF TREATING RESPIRATORY DISORDERS 审中-公开
公开(公告)号：WO2010120511A3
公开(公告)日：2010-10-21
申请号：PCT/US2010/029379
申请日：2010-03-31
申请人： ALTAIR THERAPEUTICS, INC. , ISIS PHARMACEUTICALS, INC. , GREGORY, Susan , KARRAS, James, G. , CROSBY, Jeffrey, R. , YU, Zhengrong , GEARY, Richard, S.
发明人： GREGORY, Susan , KARRAS, James, G. , CROSBY, Jeffrey, R. , YU, Zhengrong , GEARY, Richard, S.
IPC分类号： C12N15/113 , C07K14/715 , A61K48/00
摘要： Disclosed herein are methods for treating respiratory disorders via administration of antisense compounds targeting IL-4Rα. Provided herein, for example, are compositions and methods for managing, treating, ameliorating, preventing and/or delaying the onset of pulmonary inflammation, airway hyperreactivity and/or loss of lung function, or a symptom thereof in a subject. Further provided, for example, are compositions and methods of inducing or augmenting hypo-responsiveness, non-responsiveness or tolerance to an antigen in a subject. Also provided, for example, are compositions and methods of enhancing the efficacy of a vaccine in a subject. In certain embodiments, the compositions and methods provided herein utilize an antisense compound 12 to 35 nucleobases in length targeted to a nucleic acid molecule encoding human IL-4 receptor alpha IL-4Rα, wherein said antisense compound inhibits expression of human IL-4Rα protein and/or expression of functional IL-4 and IL- 13 receptors.

3. 发明申请

WO2007136988A3 COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF GCCR 审中-公开
标题翻译：化合物和调节GCCR表达的方法
公开(公告)号：WO2007136988A3
公开(公告)日：2009-05-07
申请号：PCT/US2007068410
申请日：2007-05-07
申请人： ISIS PHARMACEUTICALS INC , BHANOT SANJAY , GEARY RICHARD S , MCKAY ROBERT , MONIA BRETT P , SETH PUNIT P , SIWKOWSKI ANDREW M , SWAYZE ERIC E , WANCEWICZ EDWARD
发明人： BHANOT SANJAY , GEARY RICHARD S , MCKAY ROBERT , MONIA BRETT P , SETH PUNIT P , SIWKOWSKI ANDREW M , SWAYZE ERIC E , WANCEWICZ EDWARD
IPC分类号： A61K31/70 , C07H21/04 , C12N5/00 , C12N15/113
CPC分类号： C12N15/113 , C12N15/1137 , C12N2310/11 , C12N2310/31 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , C12N2310/341 , C12N2310/3515 , C12Y203/0102 , C12N2310/3521
摘要： The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
摘要翻译：本公开描述了短反义化合物，包括含有化学修饰的高亲和性单体长度为8-16个单体的化合物。某些此类短反义化合物可用于减少细胞，组织和动物中的靶核酸和/或蛋白质，从而增强效力并改善治疗指数。因此，本文提供了包含用于体内降低靶RNA的高亲和性核苷酸修饰的短反义化合物。这种短反义化合物在比先前描述的反义化合物更低的剂量下是有效的，从而降低了毒性和治疗成本。另外，所描述的短反义化合物具有更大的口服给药潜力。

4. 发明申请

WO2007134014A3 COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF GCGR 审中-公开
标题翻译：化合物和方法用于调节GCGR的表达
公开(公告)号：WO2007134014A3
公开(公告)日：2009-04-09
申请号：PCT/US2007068412
申请日：2007-05-07
申请人： ISIS PHARMACEUTICALS INC , BHANOT SANJAY , GEARY RICHARD S , MCKAY ROBERT , MONIA BRETT P , SETH PUNIT P , SIWKOWSKI ANDREW M , SWAYZE ERIC E , WANCEWICZ EDWARD
发明人： BHANOT SANJAY , GEARY RICHARD S , MCKAY ROBERT , MONIA BRETT P , SETH PUNIT P , SIWKOWSKI ANDREW M , SWAYZE ERIC E , WANCEWICZ EDWARD
IPC分类号： A61K31/70 , C07H21/02 , C07H21/04 , C12N5/00 , C12N15/113 , C12Q1/68
CPC分类号： C12N15/113 , C12N15/1137 , C12N2310/11 , C12N2310/31 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , C12N2310/341 , C12N2310/3515 , C12Y203/0102 , C12N2310/3521
摘要： The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
摘要翻译：本公开描述了短反义化合物，包括长度为化学修饰的高亲和力单体8-16单体的这类化合物。某些这样的短反义化合物可用于在增加的效力和改善的治疗指数的细胞，组织和动物中还原靶核酸和/或蛋白质。因此，本文提供了包含用于在体内降低靶RNA的高亲和力核苷酸修饰的短反义化合物。这样的短反义化合物在比以前描述的反义化合物低的剂量下是有效的，允许降低毒性和治疗成本。此外，所述短反义化合物具有更大的口服给药潜力。

5. 发明申请

WO2007146511A8 COMPOUNDS AND METHODS FOR MODULATING GENE EXPRESSION 审中-公开
标题翻译：化合物和调节基因表达的方法
公开(公告)号：WO2007146511A8
公开(公告)日：2009-04-02
申请号：PCT/US2007068401
申请日：2007-05-07
申请人： ISIS PHARMACEUTICALS INC , BHANOT SANJAY , GEARY RICHARD S , MCKAY ROBERT , MONIA BRETT P , SETH PUNIT P , SIWKOWSKI ANDREW M , SWAYZE ERIC E , WANCEWICZ EDWARD
发明人： BHANOT SANJAY , GEARY RICHARD S , MCKAY ROBERT , MONIA BRETT P , SETH PUNIT P , SIWKOWSKI ANDREW M , SWAYZE ERIC E , WANCEWICZ EDWARD
IPC分类号： C12N15/113
CPC分类号： C12N15/113 , C12N15/1137 , C12N2310/11 , C12N2310/31 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , C12N2310/341 , C12N2310/3515 , C12Y203/0102 , C12N2310/3521
摘要： The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
摘要翻译：本公开描述了短反义化合物，包括长度为化学修饰的高亲和力单体8-16单体的这类化合物。某些这样的短反义化合物可用于在增加的效力和改善的治疗指数的细胞，组织和动物中还原靶核酸和/或蛋白质。因此，本文提供了包含用于在体内降低靶RNA的高亲和力核苷酸修饰的短反义化合物。这样的短反义化合物在比以前描述的反义化合物低的剂量下是有效的，允许降低毒性和治疗成本。此外，所述短反义化合物具有更大的口服给药潜力。

6. 发明申请

WO2007146511A3 COMPOUNDS AND METHODS FOR MODULATING GENE EXPRESSION 审中-公开
标题翻译：化合物和调节基因表达的方法
公开(公告)号：WO2007146511A3
公开(公告)日：2008-06-12
申请号：PCT/US2007068401
申请日：2007-05-07
申请人： ISIS PHARMACEUTICALS INC , BHANOT SANJAY , GEARY RICHARD S , MCKAY ROBERT , MONIA BRETT P , SETH PUNIT P , SIWKOWSKI ANDREW M , SWAYZE ERIC E , WANCEWICZ EDWARD
发明人： BHANOT SANJAY , GEARY RICHARD S , MCKAY ROBERT , MONIA BRETT P , SETH PUNIT P , SIWKOWSKI ANDREW M , SWAYZE ERIC E , WANCEWICZ EDWARD
IPC分类号： C12N15/113
CPC分类号： C12N15/113 , C12N15/1137 , C12N2310/11 , C12N2310/31 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , C12N2310/341 , C12N2310/3515 , C12Y203/0102 , C12N2310/3521
摘要： The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
摘要翻译：本公开描述了短反义化合物，包括长度为化学修饰的高亲和力单体8-16单体的这类化合物。某些这样的短反义化合物可用于在增加的效力和改善的治疗指数的细胞，组织和动物中还原靶核酸和/或蛋白质。因此，本文提供了包含用于在体内降低靶RNA的高亲和力核苷酸修饰的短反义化合物。这样的短反义化合物在比以前描述的反义化合物低的剂量下是有效的，允许降低毒性和治疗成本。此外，所述短反义化合物具有更大的口服给药潜力。

7. 发明申请

WO2007134014A2 COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF GCGR 审中-公开
标题翻译：化合物和方法用于调节GCGR的表达
公开(公告)号：WO2007134014A2
公开(公告)日：2007-11-22
申请号：PCT/US2007/068412
申请日：2007-05-07
申请人： ISIS PHARMACEUTICALS, INC. , BHANOT, Sanjay , GEARY, Richard, S. , MCKAY, Robert , MONIA, Brett, P. , SETH, Punit, P. , SIWKOWSKI, Andrew, M. , SWAYZE, Eric, E. , WANCEWICZ, Edward
发明人： BHANOT, Sanjay , GEARY, Richard, S. , MCKAY, Robert , MONIA, Brett, P. , SETH, Punit, P. , SIWKOWSKI, Andrew, M. , SWAYZE, Eric, E. , WANCEWICZ, Edward
IPC分类号： A62D3/30
CPC分类号： C12N15/113 , C12N15/1137 , C12N2310/11 , C12N2310/31 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , C12N2310/341 , C12N2310/3515 , C12Y203/0102 , C12N2310/3521
摘要： The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo . Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
摘要翻译：本公开描述了短反义化合物，包括长度为化学修饰的高亲和力单体8-16单体的这类化合物。某些这样的短反义化合物可用于在增加的效力和改善的治疗指数的细胞，组织和动物中还原靶核酸和/或蛋白质。因此，本文提供了包含用于在体内降低靶RNA的高亲和力核苷酸修饰的短反义化合物。这样的短反义化合物在比以前描述的反义化合物低的剂量下是有效的，允许降低毒性和治疗成本。此外，所述短反义化合物具有更大的口服给药潜力。

8. 发明申请

WO2007131238A3 COMPOUNDS AND METHODS FOR MODULATING EXPRESSION APOB 审中-公开
公开(公告)号：WO2007131238A3
公开(公告)日：2007-11-15
申请号：PCT/US2007/068403
申请日：2007-05-07
申请人： ISIS PHARMACEUTICALS , INC. , BHANOT, Sanjay , GEARY, Richard, S. , MCKAY, Robert , MONIA, Brett, P. , SETH, Punit, P. , SIWKOWSKI, Andrew, M. , SWAYZE, Eric, E. , WANCEWICZ, Edward
发明人： BHANOT, Sanjay , GEARY, Richard, S. , MCKAY, Robert , MONIA, Brett, P. , SETH, Punit, P. , SIWKOWSKI, Andrew, M. , SWAYZE, Eric, E. , WANCEWICZ, Edward
IPC分类号： A61K31/70 , C07H21/02 , C07H21/04 , C12Q1/68
摘要： The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.

9. 发明申请

WO03018134A2 BIOADHESIVE COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DRUG ABSORPTION 审中-公开
标题翻译：生物降解组合物和增强型胶囊吸收的方法
公开(公告)号：WO03018134A2
公开(公告)日：2003-03-06
申请号：PCT/US0226925
申请日：2002-08-22
申请人： ISIS PHARMACEUTICALS INC , TENG CHING-LEOU , WEINBACH SUSAN P , TILLMAN LLOYD G , GEARY RICHARD S , HARDEE GREGORY E
发明人： TENG CHING-LEOU , WEINBACH SUSAN P , TILLMAN LLOYD G , GEARY RICHARD S , HARDEE GREGORY E
IPC分类号： C12N15/09 , A61K9/06 , A61K9/08 , A61K9/14 , A61K9/16 , A61K9/20 , A61K9/24 , A61K9/28 , A61K9/50 , A61K31/565 , A61K31/7088 , A61K38/00 , A61K38/43 , A61K47/08 , A61K47/12 , A61K47/14 , A61K47/16 , A61K47/18 , A61K47/22 , A61K47/28 , A61K47/32 , A61K47/34 , A61K47/36 , A61K47/38 , A61K47/42 , A61K48/00 , A61P1/00 , A61P5/00 , A61P5/24 , A61P9/00 , A61P9/08 , A61P9/12 , A61P11/10 , A61P11/14 , A61P19/00 , A61P25/02 , A61P25/20 , A61P25/24 , A61P29/00 , A61P31/04 , A61P35/00 , A61P43/00 , A61P
CPC分类号： A61K9/5084 , A61K9/1635 , A61K9/1641 , A61K9/1652 , A61K9/2077
摘要： Compositions and methods for enhanced intestinal drug absorption. The formulation comprises a first population of carrier particles comprising a drug and a bioadhesive compound and a second population of carrier particles comprising a penetration enhancer. The bioadhesive extends the residence time of the drug and its absorptive potential across the portion of the intestinal mucosa made permeable by the penetration enhancer.
摘要翻译：增强肠吸收药物的组合物和方法。制剂包含第一组载体颗粒，其包含药物和生物粘附性化合物，以及包含渗透促进剂的第二种载体颗粒。生物粘附剂延长了药物的停留时间及其吸收势能穿过穿透增强剂可透过的肠粘膜部分。

10. 发明申请

WO2008118883A1 ADMINISTERING ANTISENSE OLIGONUCLEOTIDES COMPLEMENTARY TO HUMAN APOLIPOPROTEIN B 审中-公开
标题翻译：对人类APOLIPOPROTEIN B进行补充的反义寡核苷酸
公开(公告)号：WO2008118883A1
公开(公告)日：2008-10-02
申请号：PCT/US2008/058072
申请日：2008-03-24
申请人： ISIS PHARMACEUTICALS, INC. , GEARY, Richard, S. , YU, Zhengrong , WEDEL, Mark, K. , TRIBBLE, Diane
发明人： GEARY, Richard, S. , YU, Zhengrong , WEDEL, Mark, K. , TRIBBLE, Diane
IPC分类号： C12N15/11 , A61K31/7088 , A61P3/06
CPC分类号： C12N15/113 , C12N2310/11 , C12N2310/315 , C12N2310/321 , C12N2310/3341 , C12N2310/341 , C12N2310/346 , C12N2320/32 , C12N2310/3525
摘要： Methods for long-term lowering of lipid levels in human subjects and for the treatment of conditions associated with elevated LDL-cholesterol and elevated ApoB are provided.
摘要翻译：提供了长期降低人类受试者脂质水平和治疗与升高的低密度脂蛋白胆固醇和升高的ApoB相关的病症的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式